MHRA issues Medicine Defect Information about Aripiprazole
The regulatory body has issued guidance based on a complaint that stated a precipitate formed in Aripiprazole 1mg/ml oral solution.
List view / Grid view
The regulatory body has issued guidance based on a complaint that stated a precipitate formed in Aripiprazole 1mg/ml oral solution.
Novel particles could be incorporated into topical creams to treat dermatological conditions without systemic exposure to drugs.
US researchers have stated a newly approved HIV pre-exposure prophylaxis (PrEP) therapy does not have benefits that warrant its price tag and could deter generic competition.
Development of a new method to create chiral rotaxanes has allowed researchers to show they could be ideal environments for catalysts.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
Researchers have identified a tiny protein in scorpion venom that rapidly accumulates in joint cartilage to deliver arthritis drugs in a pre-clinical study.
Tests conducted by an online pharmacy has revealed high levels of NMDA in the diabetes drug metformin, prompting the company to press for a recall.
A new vaccine formulation has been created by researchers, which uses a peelable film during drying to preserve the medicine.
The EMA has released an update on nitrosamines in drugs, saying that work is continuing to prevent and manage these impurities.
Researchers have developed a solid ‘cryogel’ vaccine that has been successful in combatting acute myeloid leukaemia in mice. How was this new formulation discovered and what potential does it have for cancer patients?
Ranitidine tablets have been recalled due to the possibility of the products containing unacceptable levels of NDMA.
Two companies have announced their partnership to work on the 3D printing of tablets for use in clinical trials.
Chemspec Europe, the International Exhibition for Fine and Speciality Chemicals, returns to Cologne for its 35th edition. From 27 – 28 May 2020, renowned manufacturers, suppliers and distributors of fine and speciality chemicals present their latest products, services and research findings to a dedicated audience of industry experts.
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
Researchers have developed a new mixture of oil and hydrogel that releases drugs in a controlled fashion, preventing overdosing.